Question explored with the scientific record
What if Digoxin was used for years and then stopped without replacing it
The short version: stopping digoxin without replacing it with another heart-failure drug carries a real risk of worsening heart failure, but the evidence is old, the drug is narrow, and the real question is why you were on it in the first place.
The best evidence on stopping digoxin comes from two small, manufacturer-independent trials from the early 1990s. The PROVED trial (113 patients on digoxin plus diuretics) found that withdrawing digoxin led to a higher rate of worsening heart failure [2]. The RADIANCE trial (178 patients on digoxin, diuretics, and ACE inhibitors) found the same: stopping digoxin worsened exercise duration [2]. Both trials were run before beta-blockers became standard, so they do not tell you what happens when digoxin is stopped in a patient who is also on carvedilol or metoprolol. A later analysis from the carvedilol trials found that patients on digoxin plus carvedilol had a 33% hospitalization rate, while those on carvedilol alone had a 23% rate [3]. That is not a withdrawal study, but it suggests that in the modern era, digoxin adds little on top of a beta-blocker.
The mechanism is straightforward. Digoxin blocks the sodium-potassium pump in heart cells, increasing the force of contraction [4]. It also lowers norepinephrine and renin levels, which reduces the workload on the heart [2]. When you stop it, those effects reverse. The heart has not adapted to the drug: a 1993 study of explanted hearts found no upregulation of the digoxin receptor after chronic use, meaning the pump density does not increase to compensate [4]. So stopping digoxin is a real loss of support, not a taper off a crutch the body has learned to do without.
But digoxin is a narrow drug. It reduces hospitalizations but has never been shown to reduce mortality. The massive DIG trial (6,800 patients) found no survival benefit [2]. It is a symptomatic treatment, not a disease-modifier. If you are on digoxin and your doctor wants to stop it, the safe path is to make sure you are on the drugs that do save lives: an ACE inhibitor or ARB, a beta-blocker, and often a mineralocorticoid receptor antagonist. The 2014 meta-analysis on medication withdrawal in stable heart failure found that stopping RAAS inhibitors or beta-blockers increased hospitalizations without any mortality benefit [1]. That is the opposite of what you want.
| Trial | Population | What happened when digoxin was stopped |
|---|---|---|
| PROVED (1993) | 113 patients on digoxin + diuretics | Higher rate of worsening heart failure [2] |
| RADIANCE (1993) | 178 patients on digoxin + diuretic + ACE inhibitor | Worsened exercise duration [2] |
| Carvedilol analysis (2000) | 669 on digoxin + carvedilol vs 234 on carvedilol alone | Hospitalization 33% vs 23% [3] |
My call: stopping digoxin without replacing it with a beta-blocker or ACE inhibitor is risky and likely to cause a relapse of heart failure symptoms. If you are already on those drugs, the risk is lower but not zero. Confidence: moderate, because the key trials are 30 years old and predate modern combination therapy.
Sources used 4
-
Can Medications be Safely Withdrawn in Patients With Stable Chronic Heart Failure? Systematic Review and Meta-analysis
This systematic review and meta-analysis investigates the safety and outcomes of medication withdrawal in patients with stable chronic heart failure, revealing that discontinuation of RAAS inhibitors and beta-blockers is discouraged due to increased hospitalizations without mort…
DOI: 10.1016/j.cardfail.2014.04.013 -
The use of digitalis in heart failure
A comprehensive review of digitalis/digoxin in heart failure, detailing pharmacology, hemodynamic and neurohormonal effects, and a synthesis of randomized and observational studies showing symptomatic/hemodynamic benefits and reduced hospitalizations, but with inconsistent morta…
DOI: 10.1016/s0146-2806(96)80001-6 -
Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity in patients with chronic heart failure
This study investigates the effects of concomitant digoxin and carvedilol therapy on mortality and morbidity in patients with chronic heart failure, revealing no clear additional benefit of digoxin when combined with carvedilol.
DOI: 10.1016/s0002-9149(00)01146-2 -
No adaptation to digitalization as evaluated by digitalis receptor (Na,K-ATPase) quantification in explanted hearts from donors without heart disease and from digitalized recipients with end-stage heart failure
This study quantified Na,K-ATPase (digitalis receptor) in explanted human hearts from donors without heart disease and from digoxin-treated recipients with end-stage heart failure, finding no evidence of upregulation with digitalization and an average receptor occupancy around 2…
DOI: 10.1016/0002-9149(93)90720-W